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Abstract
Hepatitis C virus infection is closely related to lymphoproliferative disorders (LPDs), including mixed cryoglobulinemia (MC)
and some lymphomas. Modification of the expression of specific microRNAs (miRNAs) has been associated with different
autoimmune diseases and/or LPDs. No data exist about the modifications in miRNA expression in HCV-associated LPDs. The
aim of this study was to analyze the expression levels of a panel of miRNAs previously associated with autoimmune/LPDs in
a large population of HCV patients with and without MC or non-Hodgkin’s lymphoma (NHL), to identify potential markers of
evolution of HCV infection. PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated
by real-time PCR in 167 HCV patients (75 with MC [MC-HCV], 11 with HCV-associated NHL [NHL-HCV], 81 without LPD [HCV])
and in 35 healthy subjects (HS). A significant increase in miR-21 (p,0.001), miR-16 (p,0.01) and miR-155 (p,0.01)
expression was detected in PBMCs from only NHL patients whereas a significant decrease in miR-26b was detected in both
MC and NHL subjects (p,0.01) when compared to HS and HCV groups. A restoration of miR-26b levels was observed in the
post-treatment PBMCs of 35 HCV-MC patients experiencing complete virological and clinical response following antiviral
therapy. This study, for the first time, shows that specific microRNAs in PBMC from HCV patients who developed MC and/or
NHL are modulated differently. The specific, reversible downregulation of miR-26b strongly suggests the key role it plays in
the pathogenesis of HCV-related LPDs and its usefulness as a biomarker of the evolution of HCV infection to these disorders.
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Introduction
Mixed cryoglobulinemia (MC) is both an autoimmune and
lymphoproliferative disorder (LPD) characterized by circulating
immune complexes named cryoglobulins (CGs) and composed of
polyclonal IgGs (including anti-HCV Ig) and mono- or polyclonal
IgM with rheumatoid factor (RF) activity, sustained by the clonal
expansion of RF B cells [1,2,3,4]. This is a benign, but pre-
lymphomatous condition whose clinical manifestations -the so-
called MC syndrome- are secondary to systemic vasculitis of the
small/medium vessels [5,6,7]. MC is strongly associated with
hepatitis C virus (HCV) infection: 80–90% of MC patients are
HCV positive (in Italy .95%) and from 40 to 60% of HCV
patients have circulating cryoglobulins, with 5–30% of these latter
patients having a MC syndrome. MC is frequently characterized by
bone marrow and/or liver infiltrates closely resembling non-
Hodgkin’s Lymphoma (NHL) [5], therefore, it was hypothesized
that HCV may be involved in the pathogenesis of B cell-NHL as
well [8,9]. This hypothesis was substantiated by several observa-
tions, including the significantly high prevalence of HCV infection
in NHL patients in several studies [10], as well as the resolution or
prevention of the lymphatic neoplasia after effective antiviral
therapy [11,12]. Therefore, since HCV infects about 200 million
individuals worldwide, the number of patients at risk for LPD
complications is substantial.
The mechanisms involved in the evolution of HCV infection to
LPDs are still not completely understood. The key role played by
persistent HCV infection of the peripheral blood mononuclear
cells (PBMCs) with a strong and sustained immune stimulation by
HCV antigens, the cross-linking of CD81 by the HCV envelope
protein E2 as well as the determination of t(14;18) translocation
and/or other events inhibiting B-cell apoptosis, has been pre-
viously well documented [10,13].
The development of MC and its evolution into a frank
syndrome in only a portion of HCV-positive patients and the
variable prevalence of this disease in different ethnic groups,
strongly suggest that individual, genetic and epigenetic determi-
nants are major contributions. This is corroborated by reports that
have failed to identify specific viral variants associated with HCV-
related LPDs [14], meaning that the host genetic background
seems to play a pivotal role in determining susceptibility to MC in
HCV subjects [15]. Specific HLA patterns closely associated with
the development of MC have also been described [16].
In the last decade it has become evident that, together with
genetic predisposition, epigenetic factors such as microRNA
(miRNAs) expression can give an extremely important contribu-
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tion to the pathogenesis of several diseases. The microRNAs are
a class of endogenous 19-25-nucleotide long, non-coding RNA
molecules regulating a wide variety of other genes by blocking the
translation of complementary mRNAs. Therefore, miRNAs are
important in a broad range of physiological and pathological
processes and, as master modulators of gene expression, they are
instrumental in regulating immune system development, normal
immune functions and autoimmunity [17,18,19].
Interesting data demonstrated the essential role of liver-specific
miRNA, miR-122, in HCV replication [20] and the miRNA
pattern seems to be deregulated by HCV in liver cancer [21].
Modifications of miRNA expression pattern have been demon-
strated for several types of human cancers [22,23] as well as for
a variety of autoimmune/lymphoproliferative disorders.
The number of miRNAs involved in the initiation and
progression of human cancers is continuously increasing and such
molecules have been designated as oncogenic miRNAs (onco-
miRNAs) [24].
Since miRNAs control critical steps of the immune system and
different stages of the hematopoietic maturation process, their
misexpression is reputed to be the cause of several blood
malignancies, correlating also with prognosis and phenotype.
From the first evidence of the relevance of miRNAs in lymphoid
tumors, several studies have confirmed the involvement of some
cancer-related and newly identified miRNAs, namely miR-155,
miR-146a, miR-21 and miR26b, in the pathogenesis of different
subtypes of lymphomas including some HCV-related ones
(marginal zone lymphoma –MZL and diffuse large B cell
lymphoma -DLBCL) [25,26,27]. MiR-21 and miR-26b have been
also associated with hepatocellular carcinoma development and
worst outcome after liver cancer therapy, respectively [28,29].
In the field of autoimmune diseases, the amplest data are
available for rheumatoid arthritis (RA). Several reports have
described altered miRNA expression in the synovium of patients
with RA, indicating upregulation of miR-146a in human synovial
tissue [30] and in the peripheral blood of RA patients, together
with the upregulation of miR-155 and miR-16 [31]. The
upregulation of miR-155, miR-146, miR-16 and miR-132 in
synovial fibroblasts and PBMCs isolated from RA patients further
confirms the involvement of miRNAs in the pathogenesis of such
disorders [30,31,32]. The mechanisms through which these
upregulated miRNAs contribute to RA pathogenesis are still not
clear, but they are probably implicated in fuelling the chronic
inflammatory processes.
Emerging evidence also exists for an increasingly interconnected
network of miRNA dysregulation in systemic lupus erythematosus
(SLE). Studies to date reveal a differential expression profile of
several miRNAs in PBMCs, particularly in T cells isolated from
SLE patients in comparison to healthy subjects (for a complete
review [33]).
Although several unsolved issues about the specific mechanisms
of action of miRNAs in the pathogenesis of such diseases need to
be resolved, it is already clear that they have a huge potential as
diagnostic and prognostic biomarkers of disease type and severity.
To date, very limited data exist about the miRNA expression
pattern in HCV-related extrahepatic disorders and, in particular,
no information is available about HCV-related MC. In this light,
in the present study we evaluated the expression levels of a panel of
selected miRNAs previously shown to be modified in autoim-
mune/lymphoproliferative disorders, in a large number of well
characterized patients affected by HCV-related LPDs in order to
identify miRNAs specifically modified in such disorders and




We studied 167 chronically HCV-infected patients, consecu-
tively recruited from January 2009 to December 2010, with the
following characteristics: 75 with MC [MC-HCV] (19 males,
mean age 60.6614.5 yr), 11 with HCV-associated NHL [NHL-
HCV] (2 males, mean age 60.566.55 yr), 81 without MC or NHL
or any signs or symptoms of autoimmune/lymphoproliferative
disorder [HCV, pathological control] (60 males, mean age
55.1612.1 yr), and 35 healthy blood donors (HS) as negative
controls (Table 1). We also included 35 patients with HCV-
unrelated liver disease (patients with chronic HBV hepatitis [34],
consecutively recruited for anti-HBV treatment in the same period
of time; 25 males, mean age 56.3611.4 yr). The main clinical
manifestations of MC-HCV patients are summarized in Table 2.
The majority (8/11) of HCV patients with NHL also harbored
MC and MC-related symptoms including purpura (75%),
arthralgia (65%), peripheral neuropathy (53%), renal involvement
(11%), sicca syndrome (20%), with frequency rates similar to MC
patients without NHL.
The MC-HCV group included a subgroup of 35 patients (5
males, mean age 52.965.2 yr) also belonging to another study
(Giannini et al, manuscript in preparation) analyzing the long-term
behavior of MC-HCV patients undergoing sustained virological
response to antiviral therapy with pegylated interferon and
ribavirin according to standard protocols [35,36]. This subgroup
of patients experienced both complete viral eradication and MC
clinical response. Biological samples from these patients were
analyzed both before treatment and 6 months after the end of
therapy. HCV infection was proven by detecting circulating anti-
HCV antibodies (EIA-2 and RIBA-2, Ortho Diagnostic Systems,
Raritan, NJ) and HCVRNA (AMPLICORH HCV Test, v2.0.
Roche Diagnostics, Alameda, CA). HCV genotype was de-
termined by a commercial, certified, diagnostic test (VERSANT
HCV Genotype 2.0, Siemens Healthcare Diagnostics, Deerfield,
IL). Liver disease was diagnosed according to standard, previously
described criteria and was based on liver biopsy [37]. Histopa-
thology of liver samples was assessed by two independent expert
pathologists external to the study, using the METAVIR algorithm
[37].
MC was diagnosed according to previously described criteria
[38]. Serum cryoglobulin levels and characterization, complement
fraction levels, rheumatoid factor (RF) and autoantibodies were
evaluated as described [38,39,40]. In particular, MC patients had
detectable serum cryoglobulins for more than 6 months and at
least 2 of the following criteria: palpable purpura, positive IgM-RF
latex test and low C4 levels.
According to treatment inclusion criteria [41] patients had mild
to moderate MC syndrome; patients with severe/life threatening
MC syndrome were excluded.
A diagnosis of splenic marginal zone B-cell lymphoma (SMZL),
nodal marginal zone lymphoma (NMZL), and diffuse large B-cell
lymphoma (DLBCL) was done in 8, 2, and the remaining NHL
patient, respectively, according to the Revised European Amer-
ican Lymphoma Classification (REAL) [42]. The blood sampling
was performed at the diagnosis of lymphoma, and before
treatment.
All the patients included in this study provided written informed
consent in accordance with the principles of the Declaration of
Helsinki and the study was approved by the University of Florence
Ethics Committee.
MicroRNAs in HCV-Related Mixed Cryoglobulinemia
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e62965
Cell Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from
fresh anticoagulated blood by gradient precipitation on Lympho-
prep (Axis-Shield PoC AS, Oslo, Norway) according to the
manufacturer’s instructions. After the second wash, the cells were
counted and stored at 280uC. The mean storage time was
27.3567.12 months.
RNA Extraction
Total RNA was extracted using Trizol (Invitrogen, USA) from
56106 purified PBMCs according to the manufacturer’s instruc-
tions. C. elegans miR-39 synthetic RNA oligonucleotide (1.16108
copies/106 cells) was added to PBMC samples and used as
external control to monitor extraction efficiency.
Reverse Transcription and Quantitative Real-time PCR for
miRNA Expression
Reverse transcription (RT) was performed using TaqMan
MicroRNA RT kit (Applied Biosystems, CA, USA) and 160
nanograms of total RNA.
Expression levels of human miR-Let-7d, miR-16, miR-21, miR-
26b, miR-146a, miR-155 and C. elegans miR-39 were evaluated by
Real Time PCR using specific TaqMan MicroRNA Assays
(Applied Biosystems, CA, USA) according to the manufacturer’s
instructions.
Table 1. Main clinical and laboratory data of 35 healthy subjects (HS) and 167 HCV-chronically infected patients with mixed
cryoglobulinemia (MC-HCV) or HCV-related non-Hodgkin’s lymphoma (NHL-HCV) or without MC or NHL (HCV).
HS HCV MC-HCV NHL-HCV p value
(n = 35) (n=81) (n =75) (n =11)
Mean Age (years) 5565.1 55.1612.1 60.6614.5 60.566.55 p,0.05*
Sex (male/female) 24/11 60/21 19/56 2/9 p,0.05**
Histology p,0.05***
Chronic Hepatitis 66 47 9
Cirrhosis 15 28 2
Nodal marginal zone lymphoma 2
Splenic marginal zone lymphoma 8
Diffuse large B-cell lymphoma 1
ALT‘ (ULN) 0.6961.3 1.6861.19 1.0760.6 1.5460.5 ns
Viral titer (IU/mL x 106) – 3.063.9 3.567.4 3.162.2 ns
HCV genotype ns
1 53 38 6
2 14 33 3
3 12 3 1
4 2 1 1
Mean cryocrit (%) 0 0 11.7617.1 4.865.4 p,0.01u
Mean C3# (mg/dL) 132631 108623 91624 89617 ns
Mean C4` (mg/dL) 126616 105627 867 666 p,0.01u
Mean RF{ (IU/mL) 1568 1668 2736126 3226159 p,0.01u
Results are presented as mean6 standard deviation;
ns, not significant;
‘ALT, alanine aminotransferase;
ULN, upper limit of normal.
#Complement C3, normal values: 83 to 177 mg/dL;
`Complement C4, normal values: 20 to 150 mg/dL;
{Rheumatoid Factor, normal values: ,25 IU/mL.
*HS vs MC-HCV; HS vs NHL-HCV; HCV vs MC-HCV.
**HS vs MC-HCV; HS vs NHL-HCV; HCV vs MC-HCV; HCV vs NHL-HCV.
***HCV vs MC-HCV.
uHS or HCV vs MC-HCV or NHL-HCV.
doi:10.1371/journal.pone.0062965.t001
Table 2. Principal mixed cryoglobulinemia (MC)
manifestations present in the 75 HCV patients with MC (MC-
HCV).





Neuropathic symptoms 52 69.3
Renal involvement 11 14.7
Skin ulcers 8 10.7
Sicca syndrome 25 33.3
doi:10.1371/journal.pone.0062965.t002
MicroRNAs in HCV-Related Mixed Cryoglobulinemia
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Relative expression levels of the different miRNAs were
evaluated by using the 22DDct method [43], with miR-Let-7d as
internal control to normalize miRNA expression levels.
Statistical Analysis
Data are expressed as the mean 6 SD. Quantitative variables
were analyzed using one-way analysis of variance (non-parametric
ANOVA). Categorical variables were analyzed with the x2 test
and Fisher’s exact test when necessary. All tests were two-sided at
a 0.05 significance level. Analyses were performed by the Stata
v.9.0 (StataCorpLP, College Station, TX, USA).
Results
The main clinical and serological data of these patients are
reported in Table 1. The studied groups did not significantly differ
in terms of viremia titers or viral genotype distribution, whereas, as
expected, the female sex was significantly more represented in the
MC-HCV group (p,0.05), as well as older age (p,0.01) and liver
cirrhosis (p,0.05) (Table 1).
The expression levels of Let-7d resulted stable in all subjects
analyzed in the study (mean Ct: 25.1560.85, Figure 1, panel A).
Conversely, miR-16 levels showed a higher level of fluctuation
(mean Ct: 19.3364.61, Figure 1, panel B).
The expression levels of miR-146a were similar in all tested
groups although a higher range of distribution of the samples
appeared for MC-HCV patients (Figure 2, panel A).
MiR-16, miR-21 and miR-155 had similar expression profiles
among the studied groups. In fact, a significantly higher level of
these miRNAs was present in the PBMCs isolated from NHL-
HCV patients when compared to all other groups. In more detail,
miR-16 levels were 3.16 and 2.15 times more expressed in NHL
Figure 1. Identification of a reference miRNA (internal control) for relative quantification of miRNA of interest: expression levels of
Let-7d (panel A) and miR-16 (panel B) in HCV patients and controls.
doi:10.1371/journal.pone.0062965.g001
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than in HS and HCV individuals, respectively (p,0.01), and 1.54
times vs MC-HCV patients (p,0.05). MiR-21 showed a 24.51-,
4.34-, 6.98-fold induction in NHL vs HS, HCV and MC-HCV
individuals, respectively (p,0.001). Analogously, miR-155 was up-
regulated 13.12-, 3.68- and 3.79-times in NHL vs HS, HCV and
MC-HCV patients, respectively (p,0.001).
No significant differences in miR-16, miR-21 and miR-155
levels of expression were evident in HS, HCV and MC-HCV
groups.
Interestingly, when we considered the miR-26b, a strong down-
regulation was detected in MC and NHL groups when compared
to HS, HBV and HCV patients, who presented similar levels
(74651.14 and 83.61623.36 vs 162.48611.28, 160.13618.56
and 151.98+75.44, respectively; p,0.01). In the MC-HCV group,
samples obtained from 35 patients before and .6 months after
therapy-induced complete clearance of the viral infection and
complete clinical response were available. The concentration of
miR-26b in these latter samples was totally restored
(144.05680.21) to levels comparable to HS, HBV patients or
patients without LPD (HCV) (Figure 3).
Discussion
In the present study, for the first time, we analyzed modifica-
tions in the expression pattern of some miRNAs in PBMCs from
patients with HCV-positive LPDs (MC and NHL). A panel of
miRNAs previously shown to be involved in autoimmune and/or
lymphoproliferative disorders sharing analogies with HCV-related
diseases (i.e, rheumatoid arthritis, Sjogren syndrome, MZL,
DLBCL) was selected in order to identify miRNAs with a potential
value as diagnostic/prognostic markers.
A critical step in the relative quantification of miRNA
expression levels is represented by the selection of a miRNA that
is constantly expressed in patients and controls. This issue is
currently disputed and housekeeping candidates vary, depending
on the tissue/cell type analyzed. Several studies have been
conducted using the miR-16 as internal reference [44]. However,
in the present study, miR-16 expression was significantly different
in the NHL group compared to the others (Figure 2, panel B).
Conversely, miR-Let-7d showed constant and homogeneous
expression levels in PBMCs from all subjects analyzed and assured
a good estimation of the levels of the miRNA of interest.
Figure 2. Expression levels of analyzed miRNA in healthy subjects (HS), HCV, MC-HCV and NHL-HCV patients: miR-146a (panel A),
miR-16 (panel B), miR-21 (panel C) and miR-155 (panel D).
doi:10.1371/journal.pone.0062965.g002
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Consistently, Qi et al. also observed a higher reliability of miR-Let-
7d as internal control [45].
Concerning the analysis of miRNA expression, miR-146a levels
did not significantly differ in MC or NHL patients compared to
controls, in spite of previous reports describing a misregulation of
miR-146a in several autoimmune disorders, namely AR [31] and
LES [46].
A common expression profile was found for three miRNAs
frequently associated with neoplastic disorders (onco-miRNAs):
miR-16, miR-21, and miR-155. In fact, these miRNAs were up-
regulated in PBMCs from NHL patients, whereas comparable
expression levels were recorded in HCV, MC and healthy
controls. This observation suggests the potential utility of the
analysis of the onco-miRNA expression profile in HCV patients
with suspected lymphomatous evolution.
In more detail, miR-21 has been previously described as
dramatically up-regulated in cancers, specially solid, of various
origin [47]. The identified target genes of miR-21 are numerous
and mostly involved in cell cycle regulation and suppression of
growth and proliferation and, according to computational analysis,
several other targets remain to be identified [47]. The upregula-
tion of miR-21 in HCV-associated lymphoma patients we describe
in the present study is consistent with recent data concerning
splenic SMZL [26].
MiR-155 is another very interesting miRNA involved in the
pathogenesis of several autoimmune disorders [48] as well as
different types of lymphoma [49,50]. Previous reports have
indicated miR-155 as a regulator of activation-induced cytidine
deaminase (AID), a potent DNA mutator that has been involved in
HCV-mediated lymphomagenesis [51,52]. These data justify the
analysis of miR-155 expression also in HCV-related LPDs. Higher
levels of miR-155 were evident only in NHL patients, a result
consistent with previously published data obtained in lymphoma
tissue. However, here we show that it is possible to reproduce
similar results also in PBMC samples with an evident translational
potential.
Finally, of special interest was the result of miR-26b analysis,
showing a statistically significant downregulation in both MC and
NHL patients compared to controls. A recent study, focused on
HCV-positive SMZL, reported an association between this specific
LPD and miR-26b downregulation in lymphoma tissue samples,
suggesting the involvement of miR-26b downregulation in HCV-
associated lymphomagenesis [26]. Our present results confirm and
consistently expand these previous data showing the involvement
of such a miRNA, not only in the specific field of HCV-associated
SMZL, but also in MC, the most frequent HCV-related
extrahepatic disorder, as well as in different HCV-associated
NHLs including first MZL and also DLBCL. In addition, the
present study shows the interest of the determination of miRNA
expression pattern in PBMCs, obtainable through simple, non-
invasive blood sampling, thus consistently amplifying the trans-
lational potential of such a correlation. A deeper analysis of the
Figure 3. Expression levels of miR-26b in HS, HBV, HCV, MC-HCV and NHL-HCV groups and in a subgroup of MC-HCV patients after
therapy-induced clearance of the viral infection and complete clinical response (MC post Tp).
doi:10.1371/journal.pone.0062965.g003
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mononuclear cell sub-populations is ongoing and will clarify the
actual contribution to miRNA deregulation of the different cell
types.
Due to the complex and variable pattern of miRNA expression,
we introduced an additional control represented by PBMC
samples taken from the same MC patients before and after
complete HCV clearance and complete clinical response accord-
ing to previously shown criteria [53,54]. In fact, after the complete
virological and clinical response to the anti-HCV therapy, in MC
patients the downregulation of miR-26b determined before
treatment was no longer observed. Conversely, MC patients who
did not respond to the therapy and maintained HCV viremia and
MC symptoms after a 6-months washout period, showed miR-26b
expression levels comparable with pre-treatment values and with
the levels detected in MC untreated population (data not shown).
The dowregulation of miR-26b in HCV patients with LPDs, and
not in HCV patients without LPDs, before and after therapy,
suggests that the evolution of the infection to LPDs -instead of
HCV infection per se is critical. Consequently, it is conceivable that
modifications of miR-26b expression could be useful to monitor
the development of MC or NHL during the course of HCV
infection. However, further analysis of larger populations of
selected patients are needed to ascertain such hypothesis.
Actually, an interesting, still unresolved, issue concerns the
mechanisms triggered by miR-26b deregulation. A possible role
can be played by the miR-26b target, Nek6, coding for a kinase
involved in the initiation of mitosis; the overexpression of Nek6,
already observed in different tumors [55,56], could contribute to
the avoidance of cellular senescence and promote cancer pro-
gression [26]. In addition, other miR-26b targets may help
promote and/or sustain lymphomagenesis, i.e. lymphoid enhancer
factor 1 (LEF-1). LEF-1 is a nuclear transcription factor which
forms a complex with b-catenin and T-cell factor and induces
transcription of cyclin D1 and c-myc; it is transiently expressed in
the pro-B cells while it is not detectable in mature normal B
lymphocytes. LEF-1 has been recently indicated as a specific target
of miR-26b and its overexpression is associated with miR-26b
downregulation in different cell line models [57]. Several studies
have shown elevated levels of LEF-1 in human cancers, in
particular in chronic lymphatic leukemia (CLL) [58] and a very
recent study describes an alteration in LEF-1 mRNA and protein
expression in a wide cohort of DLBCLs [59]. The possible
involvement of LEF-1 in the pathogenesis of HCV-related LPDs is
currently under evaluation.
In conclusion, this study strongly suggests the relevance of
modifications of miRNA expression pattern in the pathogenesis of
HCV-related LPDs and the utility of miRNAs as potential markers
of disease evolution/progression from pre-neoplastic conditions to
the frank malignancy. Further prospective studies will be useful to
ascertain these hypotheses.
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